NecstGen’s Post

We are very pleased to announce that our CEO, Eric Halioua will be on stage today in a panel at the Cell Therapy Manufacturing & Gene Therapy Congress organized by Informa in Dublin, Ireland. At 11:30 Eric, accompanied by Imen Mestiri, Thibault Jonckheere, and George Frodsham, will address Partnership Challenges in Cell & Gene Therapy as the market conditions change. What will be discussed? - Exploring the impacts of market conditions on CGT partnerships. - Understanding the evolving landscape of collaboration between small innovators and large biotechs. - Evaluating current partnership strategies and how they can be improved. https://lnkd.in/eeWBzXk

Advancement in critical therapeutic niches is one of the factors behind the domination of specialty-based drugs in the pharma industry. CRISPR therapy, RNA-based research, and cell and gene therapy research are some of the technologies being leveraged in the specialty-based arena. What are the implications of the specialty landscape? How are primary care physicians getting familiarized with specialty-based drugs? Christina Fresta, MPH, Strategic Solutions Senior Manager at epocrates, talks about this and more here: https://bit.ly/48P3nk4 #epocrates #healthcareIT #technologyandinnovation #specialtydrugs

  Landmark Bio’s Eli Kraus, Yun Chen,Ph.D., Manish Tandon and Gregg Nyberg, demonstrate application of a rapid analytical method in cutting-edge Extracellular Vesicle (EV)-based therapy biomanufacturing. Based on widely available conventional Flow Cytometer configurations, the method development was presented at the ECI Advancing Manufacture of Cell and Gene Therapies Conference in Coronado, CA. Read about the accuracy, precision, and reliable EV quantitation by Flow Cytometry, its benefit, criticality, and limitation in directly supporting clinical EV biomanufacturing platforms. #ExtracellularVesicles #FlowCytometry  

Understanding the relationship between the hospital space, the, the clinical space and the lab is an essential step in solving the workflow challenges faced by many cell therapy labs today. Harnessing technological opportunities here will mean better, faster and safer patient access. 1️⃣ Siloing the cell lab within the CGT enterprise (clinical, laboratory and manufacturing organizations) risks complicating the flow of data in ways that can challenge a patient first approach 2️⃣ The growth potential of cell and gene therapy as an institution is, in our opinion, not limited by the size of the boxes represented here, but really by the pace at which all parts of the process can speak a shared language to amplify challenges and celebrate successes. 3️⃣ Until the software itself becomes as essential as the stethoscope or the microscope, scalability will continue to be an integrated and shared risk Watch the webinar on-demand here - https://hubs.ly/Q02xc9Mq0 #celltherapy #patientsafety #celltherapyworkflow #patientaccess #digitization

Are we ready to deliver therapies to patients quickly and efficiently? How can we address challenges of new modalities' needs? Listen my podcast where I share my view on how to pave the way for an industry alignment to deliver best practices in clinical and commercial outbound supply chains. #cellandgenetherapy #cgt #advancedtherapies #supplychainmanagement #sartorius

Great to be supporting more research into ground-breaking cell and gene therapy by funding this important network for another four years. The £17.9m in funding will bolster clinical trial infrastructure in the UK and help maintain our reputation as a location of choice for advanced therapy research. Professor Marian Knight, Scientific Director for NIHR Infrastructure said: “The NIHR is committed to ensuring that the UK provides a research environment to enable rapid assessment of new advanced therapies with the potential to transform health and care. "Partnerships such as these, linked with existing NIHR research infrastructure, will help ensure that the UK public is able to benefit from these ground-breaking new treatments." Find out more 👇 https://lnkd.in/egxMFP7U 💡 Innovate UK 🧬 Cell and Gene Therapy Catapult

Did you miss our latest webinar? No problem - we've curated an extensive library of over 20 market access webinar recordings, available upon request 💡 Our commitment is to equip you with valuable resources for your market access journey and help your team to be on the cutting edge of developments in the market access landscape. Check out some of the engaging topics we've covered recently: - Breaking down barriers to access in Europe – getting it right first time for rare diseases! - Harnessing the power of AI in HTAs to accelerate patient access - Economic modelling in cell & gene therapy – When to start and when is it too late? - Navigating pricing and reimbursement challenges for rare disease technologies Explore the full range of market access webinars, exclusively available for biopharma companies, and request recordings here: https://lnkd.in/exewTNnb #MarketAccess #PatientAccess #Webinars

Navigating the evolving cell and gene therapy landscape! Discover how to navigate the rapidly evolving cell therapy landscape, from innovative manufacturing techniques to regulatory shifts. Get insights from industry expert and RoslinCT SAB Member Michael Mendicino, Ph.D., on the challenges and opportunities ahead. Read the blog here: https://lnkd.in/eceARPD7

Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy

We hope you're having a wonderful time at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting! Don't forget to attend Thermo Fisher Scientific's sponsored session, "Revolutionizing Gene Therapy Services: A Synergistic Approach to Analytics and Scaling Up Through CDMO-CRO Collaboration," on Friday, May 10. In this session, you'll discover how collaboration between #CROs and #CDMOs can alleviate #scalability and #analytics challenges when it comes to adeno-associated viral (AAV) vector production and how these integrated organizations can expedite the development and delivery of transformative #genetherapy treatments. Learn more » https://bit.ly/4b4XDEC